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ABSTRACT
Introduction Uncomplicated urinary tract infection (UTI) in 
women is a common reason to present in general practice 
and is usually treated with antibiotics to reduce symptom 
severity and duration. Results of recent clinical trials 
indicate that non- antibiotic treatment approaches can also 
be effective. However, it remains unclear which patients 
would benefit from antibiotic treatment and which can 
effectively and safely be treated without antibiotics. This 
systematic review and meta- analysis aims to estimate 
the effect of treatment strategies to reduce antibiotic use 
in comparison with immediate antibiotic treatment and to 
identify prognostic factors and moderators of treatment 
effects. A further aim is to identify subgroups of patients 
benefiting from a specific therapy.
Methods and analysis A systematic literature search 
will be performed to identify randomised controlled trials 
which investigated the effect of treatment strategies to 
reduce antibiotic use in female adults with uncomplicated 
UTI compared with immediate antibiotic treatment. 
Therefore, the primary outcome of the meta- analysis 
is incomplete recovery. Anonymised individual patient 
data (IPD) will be collected. Aggregate data will be used 
for pairwise comparisons of treatment strategies using 
meta- analysis models with random effects accounting for 
potential between- study heterogeneity. Potential effect 
moderators will be explored in meta- regressions. For IPD, 
generalised linear mixed models will be used, which may 
be adjusted for baseline characteristics. Interactions of 
baseline variables with treatment effects will be explored. 
These models will be used to assess direct comparisons of 
treatment, but might be extended to networks.
Ethics and dissemination The local institutional review 
and ethics board judged the project a secondary analysis 
of existing anonymous data which meet the criteria for 
waiver of ethics review. Dissemination of the results will 
be via published scientific papers and presentations. Key 
messages will be promoted for example, via social media 
or press releases.
PROSPERO registration number CRD42019125804.
INTRODUCTION
Uncomplicated urinary tract infection (UTI) 
is a common condition affecting mostly 
women with a lifetime prevalence of 50% and 
is a common reason for women to present to 
general practice.1 2 Generally, primary care 
guidelines recommend immediate antibi-
otics as a first- line treatment.3 Consequently, 
UTI is among the most common causes for 
antibiotic prescription in primary care.4–8 
Strengths and limitations of this study
 ► This is the first individual patient data (IPD) meta- 
analysis to evaluate the effectiveness of experimen-
tal strategies to reduce antibiotic use in women with 
uncomplicated urinary tract infection in comparison 
with immediate antibiotic treatment.
 ► A clinical prognostic model will be developed in or-
der to identify women who can be treated without 
(immediate) antibiotics effectively and safely and to 
facilitate an individualised treatment approach.
 ► The use of IPD will allow for detailed modelling aimed 
towards personalised treatment recommendations.
 ► The joint analysis of data from several studies will 
enhance the external validity of findings and the as-
sessment thereof.
 ► The set of included studies may be subject to selec-
tion biases (eg, reporting bias, data availability bias) 
and may be heterogeneous in design, study popula-
tion and intervention used.
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Therefore, efforts to reduce their prescription are highly 
appreciated to reduce levels of antibiotic resistance. 
Physicians tend to overestimate the need and demand 
for antibiotics, and to prescribe them rather liberally 
although many women prefer non- antibiotic strategies to 
treat UTI if this is reliable and safe.2 5 9 Furthermore, the 
selective effect of antibiotics on antimicrobial resistance 
increasingly forces physicians to prescribe second- line 
antibiotics.10 Non- antibiotic treatment approaches as well 
as delayed prescription of antibiotics for UTI were tested 
in several randomised controlled trials (RCTs) showing 
reduced antibiotic use, but also delayed resolution of 
symptoms.11–16 In most of these trials, the chosen strate-
gies could substantially reduce the number of antibiotic 
courses in women with uncomplicated UTI, but this was 
traded off by a somewhat higher symptom severity or 
longer symptom duration and a few more cases of febrile 
UTI, worsening symptoms or pyelonephritis. Overall, the 
results of the trials suggest that symptomatic treatment is 
effective, but it may not be the method of choice for every 
woman with uncomplicated UTI. Thus, reducing antibi-
otic prescribing can be impeded by uncertainty regarding 
which patients with UTI symptoms would benefit from 
antibiotic treatment and which ones can effectively and 
safely be treated without (immediate) antibiotics.
There is a lack of guidance as to when immediate anti-
biotic treatment may be appropriate, and when alterna-
tive measures may be adequate. Physicians usually use 
symptoms, signs and a point- of- care test (mostly dipsticks) 
to diagnose UTI, but predicting the outcome of uncom-
plicated UTIs will enable individualised treatment 
recommendations.
Therefore, the meta- analysis aims to (1) estimate the 
effect of experimental strategies to reduce antibiotic use 
in women with uncomplicated UTI compared with imme-
diate antibiotic treatment as standard care; (2) identify 
moderators that modify treatment effects comparing 
experimental strategies with immediate antibiotic treat-
ment and (3) identify prognostic factors at baseline asso-
ciated with disease course of UTI in women allocated to 
experimental strategies and to develop a clinical predic-
tion model to support treatment decisions in women with 
UTI.
METHODS AND ANALYSIS
In this systematic review and meta- analysis, RCTs 
comparing different strategies to reduce antibiotic use in 
women with uncomplicated UTI presenting to primary 
care will be identified and investigated. Individual patient 
data (IPD) will be collected to compare strategies aimed 
at reducing antibiotic use in women with uncomplicated 
UTI and immediate antibiotic treatment as a standard of 
care. If IPD are not available, aggregated results of the 
studies will at least be used for the estimation of treat-
ment effects. The feasibility of a network meta- analysis will 
be investigated in order to allow for direct and indirect 
treatment comparisons. The present meta- analysis will be 
conducted in line with the Preferred Reporting Items for 
Systematic Reviews and Meta- Analyses (PRISMA) state-
ment.17 The PRISMA checklist can be found in the online 
supplemental file 1.
Population
The primary target population are female adults (aged 
18 or older) with symptoms of an acute UTI presenting in 
general practice. In case results are stated only for mixed 
adult/adolescent populations, these will be considered 
as well, but paediatric populations (all younger than 18 
years) will be excluded.
Interventions
The intervention is any experimental strategy to reduce 
antibiotic use (eg, symptomatic treatment with non- 
steroidal anti- inflammatory drugs, herbal treatments, 
placebo or delayed antibiotic prescription).
Controls
The control is immediate antibiotic treatment as standard 
care.
Outcomes
Related to objectives (1) and (2) the primary outcome is 
incomplete clinical recovery; defined as more than slight 
symptoms (this applies to at least one of the scores for 
dysuria, frequency, urgency that were assessed last between 
days 3 and 7) at days 3–7 or occurrence of pyelonephritis, 
febrile UTI and sepsis or subsequent antibiotic treatment 
during a follow- up of at least 14 days. To assess the primary 
outcome with respect to UTI symptoms, we chose the 
time period of 3–7 days since most RCTs demonstrated 
the duration of moderately bad or worse symptoms within 
3–4 days and a symptom resolution within 7 days in most 
of included patients.12 15 16 18 With respect to the criteria 
pyelonephritis and subsequent antibiotic treatment, we 
chose a follow- up period of at least 14 days. Uncompli-
cated UTI is a short condition and most RCTs followed up 
the patients for about 4 weeks. A longer follow- up period 
did not reveal changes regarding the complications and 
occurrence of recurrent UTI.19 For this reason and in 
order to include all available evidence on this topic, we 
chose a follow- up period of at least 14 days.
Secondary outcomes are antibiotic use (number of 
antibiotic courses) during a follow- up of at least 14 days, 
symptom burden at day 2, symptom burden at days 3–7, 
clinical recovery (defined as a symptom score of 0 for 
dysuria, frequency and urgency) at days 3–7 and recur-
rent UTI. Safety outcomes are complications (pyelone-
phritis, febrile UTI, sepsis) and (serious) adverse events 
within at least 14 days, related to the treatment or due 
to other reasons. Worsening of UTI symptoms will not 
be treated as adverse events as these are related to the 
outcome of the meta- analysis.
Related to objective (3), outcomes for prognostic 
factors at baseline will be associated with disease course 
of UTI in women allocated to experimental strategies. 
The outcomes will be: (a) recovery without antibiotics 
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within 14 days (b) subsequent antibiotic treatment within 
at least 14 days (due to persistent/worsening symptoms, 
symptom relapse) (c) complications (eg, febrile UTI, 
pyelonephritis). Candidate prognostic factors and moder-
ators will include age, presence, severity and duration 
of patient- reported symptoms (eg, dysuria, frequency, 
urgency, lower abdominal pain), physician- reported phys-
ical examination findings (eg, fever, loin pain), point- of- 
care tests (eg, dipstick test results, C reactive protein, urine 
sediment, other point- of- care tests) and other additional 
variables like the bladder incubation time, at the initial 
consultation or inclusion, if available.20 Although urine 
culture results are not available at the time of the treat-
ment decisions, we will investigate the results (positive or 
negative for the presence of uropathogens and antimicro-
bial resistance) as possible antibiotic effect moderators.
Study designs
RCTs will be included in the meta- analysis.
Search strategy
A comprehensive literature search will be conducted in 
the following databases: MEDLINE, EMBASE, Web of 
Science, Latin American and Caribbean Health Sciences 
Literature (LILACS), the Cochrane Database of System-
atic Reviews, the Cochrane Central Register of Controlled 
Trials, the Health Technology Assessment Database 
(HTA) at the Centre for Reviews and Dissemination and 
ClinicalTrials. gov.
Publications from 1990 onwards will be considered. If 
feasible, results will be filtered for ‘Clinical Study’, and 
the search will be repeated without filter, but with publi-
cation dates from 2018 onwards to retrieve studies that 
have only recently been added to the database and may 
not be completely indexed. The search terms including 
relevant Medical Subject Headings and keywords are 
(urinary tract infection OR urinary tract infections OR 
UTI OR bacteriuria OR pyuria OR cystitis OR pyelone-
phritis) AND (antibiotic OR antibiotics OR anti- bacterial 
agents OR anti- microbial). Detailed search strategies for 
each literature database can be found in tables 1–6 and 
under the Search strategies: additional databases section.
Reference lists of included studies and relevant reviews 
will be checked to identify any additional relevant articles 
that were not captured by the search.
Search strategies: additional databases
Latin American and Caribbean Health Sciences Literature
(tw:((mh: ‘urinary tract infections’ OR “urinary tract 
infection” OR “urinary tract infection*” OR (“urinary” 
AND “tract” AND “infection*”) OR “uti” OR mh: “bacte-
riuria” OR “bacteriuria” OR mh: “pyuria” OR “pyuria” OR 
mh: “cystitis” OR “cystitis” OR mh: “pyelonephritis” OR 
“pyelonephritis”))) AND (tw:((mh: “anti- bacterial agents” 
OR (“anti- bacterial” AND agents) OR “anti- bacterial 
agents” OR mh: “antibiotic agent” OR “antibiotic*” OR 
“anti- microbial” OR (“anti” AND “microbial”)))) AND 
(tw:((mh: “random allocation” OR (“random” AND 
“allocation”) OR “random allocation” OR “randomised” 
OR “randomized” OR “controlled” OR “Clinical”))) 
AND (tw:((mh: “clinical trials as a topic” OR (“clinical” 
AND “trial”) OR “clinical trial” OR “trial” OR “study” OR 
mh: “randomized controlled trials as a topic”))) AND 
(instance:“regional”) AND (db:(“LILACS”))
HTA Database of the Center for Reviews and Dissemination 
(limitation 1990–2019)
((urinary tract infection*) AND (bacteriuria) OR (anti-
biotic*)) and (Project record:ZDT OR Full publication 
record:ZDT) IN HTA FROM 1990 TO 2019
 ClinicalTrials. gov (applied filters: Interventional, Female, Adult 
(18–64), Older Adult (65+))
(Urinary Tract Infections OR bacteriuria OR pyuria OR 
cystitis OR pyelonephritis) AND (antibiotics OR antibi-
otic OR anti- bacterial OR anti- microbial)
Study selection and quality assessment
Screening of the search results for relevant studies will be 
done by two reviewers independently. Title and abstract 
will be screened and studies that clearly do not meet the 
Table 1 PubMed—search strategy: first search with filter 
‘Clinical Study’ and ‘1990/01/01 to 2019/12/31’
Search Query
1 “urinary tract infections”[MeSH Terms] OR 
(“urinary”[All Fields] AND “tract”[All Fields] 
AND “infections”[All Fields]) OR “urinary tract 
infections”(All Fields)
2 (“urinary”[All Fields] AND “tract”[All Fields] 
AND “infection”[All Fields]) OR “urinary tract 
infection”[All Fields]
3 UTI[All Fields]
4 “bacteriuria”[MeSH Terms] OR “bacteriuria”[All 
Fields]
5 “pyuria”[MeSH Terms] OR “pyuria”[All Fields]
6 “cystitis”[MeSH Terms] OR “cystitis”[All Fields]
7 “pyelonephritis”[MeSH Terms] OR 
“pyelonephritis”[All Fields]
8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7
9 “anti- bacterial agents”[Pharmacological Action] 
OR “anti- bacterial agents”[MeSH Terms] OR 
(“anti- bacterial”[All Fields] AND “agents”[All 
Fields]) OR “anti- bacterial agents”[All Fields]
10 “antibiotic”[All Fields] OR “antibiotics”[All Fields]
11 “anti- microbial” [All Fields] OR (“anti” [All Fields] 
AND “microbial” [All Fields])
12 #9 OR #10 OR #11
13 #8 AND #12
14 #8 AND #12 Filters: Clinical Study
15 #8 AND #12 Filters: Clinical Study; Publication 
date from 1990/01/01 to 2019/12/31
MeSH, Medical Subject Headings.
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inclusion criteria will be excluded. Any disagreements 
and all remaining studies will be rescreened by a third 
reviewer. For all studies still remaining, full texts will be 
reviewed according to the pre- specified inclusion criteria 
by the third reviewer. The decision about inclusion or 
exclusion of a study will be discussed with another inde-
pendent reviewer. RCTs in uncomplicated acute UTI in 
adult (adolescent) female patients presenting in general 
practice with any intervention to reduce antibiotic treat-
ment and (immediate) antibiotic treatment as control 
will be included. Conference abstracts will be excluded. 
If appropriate, IPD of trials that do not compare directly 
an intervention to reduce antibiotic treatment with 
(immediate) antibiotic treatment can be considered in 
explorative analyses to strengthen, if only indirectly, the 
outlined comparisons.
Study quality will be assessed independently by two 
reviewers using the Cochrane Collaboration’s tool for 
assessing risk of bias focusing on sequence generation 
and allocation sequence concealment (selection bias), 
blinding of participants and personnel (performance 
bias), blinding of outcome assessment (detection bias), 
incomplete outcome data (attrition bias) and selective 
outcome reporting (reporting bias).21 The potential for 
publication bias will be assessed using funnel plots (with 
and without studies lacking IPD) and corresponding asym-
metry tests. To assess data availability bias characteristics 
Table 2 PubMed—search strategy: additional search 
without filter ‘Clinical Study’ and from 2018 onwards (to 
retrieve studies that have only recently been added to the 
database and may not be completely indexed in PubMed)
Search Query
1 “urinary tract infections”[MeSH Terms] OR 
(“urinary”[All Fields] AND “tract”[All Fields] 
AND “infections”[All Fields]) OR “urinary tract 
infections”[All Fields]
2 (“urinary”[All Fields] AND “tract”[All Fields] AND 
“infection”[All Fields]) OR “urinary tract infection”[All 
Fields]
3 UTI(All Fields)
4 “bacteriuria”[MeSH Terms] OR “bacteriuria”[All 
Fields]
5 “pyuria”[MeSH Terms] OR “pyuria”[All Fields]
6 “cystitis”[MeSH Terms] OR “cystitis”[All Fields]
7 “pyelonephritis”[MeSH Terms] OR 
“pyelonephritis”[All Fields]
8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7
9 “anti- bacterial agents”[Pharmacological Action] 
OR “anti- bacterial agents”[MeSH Terms] OR (“anti- 
bacterial”[All Fields] AND “agents”[All Fields]) OR 
“anti- bacterial agents”[All Fields]
10 “antibiotic”[All Fields] OR “antibiotics”[All Fields]
11 “anti- microbial”[All Fields] OR (“anti”[All Fields] AND 
“microbial”[All Fields])
12 #9 OR #10 OR #11
13 “random allocation”[MeSH Terms] OR (“random”[All 
Fields] AND “allocation”[All Fields]) OR “random 
allocation”[All Fields] OR “randomised”[All Fields] 
OR “randomised”[All Fields] OR “controlled”[All 
Fields] OR “clinical”[All Fields]
14 (“clinical trials as topic”[MeSH Terms] OR 
(“clinical”[All Fields] AND “trials”[All Fields] AND 
“topic”[All Fields]) OR “clinical trials as topic”[All 
Fields] OR “trial”[All Fields]) OR “study”[All Fields]
15 #13 AND #14
16 “randomised controlled trials as topic”[MeSH 
Terms]
17 #15 OR #16
18 #8 AND #12 AND #17
19 #8 AND #12 AND #19 Filters: Publication date from 
2018/01/01 to 2019/12/31
MeSH, Medical Subject Headings.
Table 3 EMBASE—search strategy: first search with filter 
‘Controlled Clinical Trial/Randomized Controlled Trial’ and 
‘1990/01/01 to 2019/12/31’
Search Query
1 ‘urinary tract infection’/exp OR (urinary AND tract 
AND infection*) OR ‘urinary tract infection’
2 uti
3 ‘bacteriuria’/exp OR bacteriuria
4 ‘pyuria’/exp OR pyuria
5 ‘cystitis’/exp OR cystitis
6 ‘pyelonephritis’/exp OR pyelonephritis
7 #1 OR #2 OR #3 OR #4 OR #5 OR #6
8 antiinfective agent’/exp OR (‘anti- bacterial’ AND 
agent*)
9 ‘antibiotic agent’/exp OR ‘antibiotic*’
10 ‘anti- microbial’ OR (anti AND microbial)
11 #8 OR #9 OR #10
12 #7 AND #11
13 #12 AND (‘controlled clinical trial’/de OR 
‘randomized controlled trial’/de OR ‘randomized 
controlled trial (topic)’/de)
14 #12 AND (‘controlled clinical trial’/de OR 
‘randomized controlled trial’/de OR ‘randomized 
controlled trial (topic)’/de) AND(1990–2019)/py
15 #12 AND (‘controlled clinical trial’/de OR 
‘randomized controlled trial’/de OR ‘randomized 
controlled trial (topic)’/de) AND(1990–2019)/py AND 
(embase)/lim
16 #12 AND (‘controlled clinical trial’/de OR 
‘randomized controlled trial’/de OR ‘randomized 
controlled trial (topic)’/de) AND(1990–2019)/py AND 
(medline)/lim
17 #14 NOT #16
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of the studies with IPD and those without IPD will be 
compared.22
Data extraction and IPD collection
For the IPD- meta- analysis anonymised data on indi-
vidual patient level will be requested either in electronic 
form via standardised data extraction sheets and will be 
formatted in a consistent way to permit reanalysis. As the 
rating scales vary across some of the studies, the defined 
symptom severity for the primary and secondary outcomes 
may need to be rescaled. Data (baseline characteristics, 
outcomes and study characteristics) will be checked for 
accordance with the published data. If data appear incon-
sistent or unclear, this will be resolved by queries to the 
investigators. The investigators of currently nine available 
studies have been contacted in advance via personnel 
communication and agreed to provide IPD of their trials. 
Authors of further studies, which will be identified during 
the systematic literature search, will be contacted via 
email and asked to participate and to provide IPD of their 
trials. A comprehensive list of the requested variables are 
in the online supplemental file 2. If no IPD are accessible, 
aggregated data on baseline characteristics, treatments, 
symptoms and outcomes measures will be extracted from 
the publication in standardised forms by two reviewers 
independently.
Table 4 EMBASE—search strategy: additional search 
without filter ‘Controlled Clinical Trial/Randomized 
Controlled Trial’ and from 2018 onwards (to retrieve studies 
that have only recently been added to the database and may 
not be completely indexed in EMBASE)
Search Query
1 ‘urinary tract infection’/exp OR (urinary AND tract 
AND infection*) OR ‘urinary tract infection’
2 uti
3 ‘bacteriuria’/exp OR bacteriuria
4 ‘pyuria’/exp OR pyuria
5 ‘cystitis’/exp OR cystitis
6 ‘pyelonephritis’/exp OR pyelonephritis
7 #1 OR #2 OR #3 OR #4 OR #5 OR #6
8 antiinfective agent’/exp OR (‘anti- bacterial’ AND 
agent*)
9 ‘antibiotic agent’/exp OR ‘antibiotic*’
10 ‘anti- microbial’ OR (anti AND microbial)
11 #8 OR #9 OR #10
12 ‘randomization’/exp OR (random AND allocation) 
OR randomi$ed
13 ‘clinical trial’/exp OR ‘clinical study’/exp OR 
(clinical AND trial) OR (clinical AND study) OR 
‘controlled study’/exp OR ‘controlled study’
14 #12 AND #13
15 ‘randomized controlled trial’/exp AND topic
16 #14 OR #15
17 #7 AND #11 AND #16
18 #7 AND #11 AND #16 AND(2018–2019)/py
19 #7 AND #11 AND #16 AND(2018–2019)/py AND 
(medline)/lim
20 #18 NOT #19
Table 5 Cochrane Library (CENTRAL and CDSR) search 
strategy (limitation 1990–2019)
Search Query (all text)
1 ‘urinary tract infection’
2 ‘urinary tract infections’
3 uti
4 ‘bacteriuria’
5 ‘pyuria’
6 ‘cystitis’
7 ‘pyelonephritis’
8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7
9 ‘anti- bacterial agents’
10 ‘antibiotic’
11 ‘anti- microbial’
12 #9 OR #10 OR #11
13 #8 AND #12
CDSR, Cochrane Database of Systematic Reviews; CENTRAL, 
Cochrane Central Register of Controlled Trials.
Table 6 Web of Science—search strategy (limitation: 
article; 1990–2019)
Search Query (all text)
1 ALL=(“urinary tract infection*” OR UTI OR 
bacteriuria OR pyuria OR cystitis OR pyelonephritis)
Indexes=SCI- EXPANDED Timespan=All years
2 ALL=(antibiotic* OR anti- microbial OR anti- 
bacterial)
Indexes=SCI- EXPANDED Timespan=All years
3 #2 AND #1
Indexes=SCI- EXPANDED Timespan=All years
4 ALL=(“random allocation”)
Indexes=SCI- EXPANDED Timespan=All years
5 ALL=(randomized OR randomised OR controlled 
OR clinical)
Indexes=SCI- EXPANDED Timespan=All years
6 ALL=(trial OR study)
Indexes=SCI- EXPANDED Timespan=All years
7 #6 AND #5
Indexes=SCI- EXPANDED Timespan=All years
8 #7 OR #4
Indexes=SCI- EXPANDED Timespan=All years
9 #8 AND #3
Indexes=SCI- EXPANDED Timespan=All years
10 (#8 AND #3) AND DOCUMENT TYPES: (Article)
Indexes=SCI- EXPANDED Timespan=1990–2019
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Analysis strategy and statistical methods
Pairwise meta- analysis methods will be used for esti-
mating treatment effects (relative to standard treatment) 
based on relevant subsets of studies. Meta- analysis will be 
carried out if at least two studies are available for compar-
ison. In order to include effect moderators or prognostic 
factors, analyses are generalised to meta- regressions. In 
all cases, analyses will be stratified by incorporating study- 
specific random effects, and, in a secondary analysis, 
possibly also centre- effects in IPD. IPD are considered 
via appropriate likelihoods (eg, binomial likelihoods for 
binary outcomes); study- level summary estimates (eg, log 
ORs) are included using an approximate normal likeli-
hood (where appropriate). In a sensitivity analysis, we will 
also incorporate the IPD in terms of a summary estimate 
in a (technically simpler) two- stage meta- analysis. The 
investigation of prognostic factors (objective (3)) will 
require IPD. Prognostic factors will also be considered in 
terms of random effects, if supported by a better model 
fit, or otherwise as fixed effects. Missing data for certain 
patients in IPD will be imputed if necessary, given that 
the missing cases only make up a minority, and that these 
may plausibly be considered missing at random.23 The 
models used all fall into the general class of generalised 
linear mixed models, a special type of hierarchical model 
accounting for variability at the patient- level as well as the 
study- level. In order to include also indirect evidence on 
treatment effects, the feasibility of a (joint) network meta- 
analysis will be explored.
Primary analyses will focus on ORs as effect measures, 
but relative risks will be explored as an alternative. Anal-
yses will be performed using Bayesian methods with 
uninformative priors for treatment effects and weakly 
informative priors for between- study variability (heteroge-
neity), as these are better suited for the case of few studies 
only.24 For objective (1), the variables urgency, frequency 
and dipstick results such as erythrocytes, leucocytes and 
nitrite will be included as main effects in the model.25–27 
Other additional variables (like age, further UTI symp-
toms, fever, urine culture results, C reactive protein, other 
point- of- care tests) will be considered in a variable selec-
tion stage. Concerning objective (2), symptom duration, 
worsening of symptoms and relapse will be considered as 
potential treatment effect moderators. Effect estimates 
(ORs or relative risks) will be quoted along with two- sided 
95% credible intervals and posterior tail probabilities. 
Model building will be done using forward selection based 
on Bayes factors (if sensible and feasible), or approxima-
tions like information criteria (eg, the deviance informa-
tion criterion). Besides pairwise comparisons of specific 
medications (eg, fosfomycin vs ibuprofen), groups of 
similar treatments will be grouped in broader categories 
(eg, first- line and second- line antibiotics, pain killers, 
herbal treatments, delayed prescription or placebo). 
Between- study variability will be visually explored in forest 
plots of (log) ORs and quantified using the SD parameter 
tau. Sensitivity of results to modelling approaches will be 
assessed for example, by varying prior assumptions for the 
heterogeneity, by considering subgroups of studies based 
on suitable geographical regions or by exclusion of indi-
vidual studies based on quality criteria. The performance 
of prognostic models (objective (3)) will be assessed in 
an internal–external cross- validation fashion.23 While the 
validation of prognostic models is fairly established, the 
evaluation of prediction models (objectives (1) and (2)) 
is an area of ongoing research.28 For this purpose it may 
be possible to use, for example, a C- statistic approach.29
Descriptive summaries are used to describe study- 
characteristics and patient- characteristics, including as 
complete as possible details on missing values. Metric 
variables are characterised by mean and SD (and range, 
where appropriate) ordinal scaled variables by median 
and percentiles. Discrete variables are summarised by 
quoting absolute or relative frequencies.
We will use the R software (including appropriate 
add- on packages, for example, LME, JAGS, STAN, 
metafor, bayesmeta, MetaStan) for all statistical analyses.
To rate the confidence in cumulative evidence, the 
strength of the body of evidence (quality or certainty 
of evidence and strength of recommendation) will be 
assessed using The Grading of Recommendations Assess-
ment, Development and Evaluation framework.30
Patient and public involvement
Our research team is collaborating with a patient advisory 
board consisting of about eight citizens which has recently 
been established at the Department of General Practice of 
the University of Wuerzburg (see http://www. allgemein-
medizin. uni- wuerzburg. de/ forschung/ buergerforum/). 
The board has been introduced to discuss the designs of 
the department’s scientific studies to ensure that they are 
comprehensible and relevant for humans.31 It has been 
invited to give feedback to the aims and outcomes of this 
review and will be involved to participate in development 
of the prognostic model. The group will also be involved 
as a patient advisory board of a practice- based research 
network in Bavaria (see http://www. allgemeinmedizin. 
uni- wuerzburg. de/ forschung/ forschungspraxennetz/).
ETHICS AND DISSEMINATION
The meta- analysis is based on previously published studies. 
The local institutional review and ethics board judged the 
project a secondary analysis of existing anonymous data 
which meet the criteria for waiver of ethics review. Data 
sharing statement according to current guidelines of 
the International Committee of Medical Journal Editors 
(ICMJE) will be required from authors providing IPD.
Dissemination of the results will be via published 
research papers in high- quality peer- reviewed open access 
journals and presentations at scientific meetings. Addi-
tionally, key messages will be promoted to clinicians and 
patients via direct mailings, communications via clinical 
research networks, social media, press releases or patient 
blogs. This work will aim to influence guidelines on 
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clinical management of UTI symptoms both on national 
(national guidelines) and international levels.
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